BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35695575)

  • 1. ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma.
    Terzolo M; Fassnacht M
    Eur J Endocrinol; 2022 Sep; 187(3):R27-R40. PubMed ID: 35695575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
    Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
    Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
    World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
    Terzolo M; Fassnacht M; Perotti P; Libé R; Kastelan D; Lacroix A; Arlt W; Haak HR; Loli P; Decoudier B; Lasolle H; Quinkler M; Haissaguerre M; Chabre O; Caron P; Stigliano A; Giordano R; Zatelli MC; Bancos I; Fragoso MCBV; Canu L; Luconi M; Puglisi S; Basile V; Reimondo G; Kroiss M; Megerle F; Hahner S; Kimpel O; Dusek T; Nölting S; Bourdeau I; Chortis V; Ettaieb MH; Cosentini D; Grisanti S; Baudin E; Berchialla P; Bovis F; Sormani MP; Bruzzi P; Beuschlein F; Bertherat J; Berruti A
    Lancet Diabetes Endocrinol; 2023 Oct; 11(10):720-730. PubMed ID: 37619579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
    Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
    J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
    Veytsman I; Nieman L; Fojo T
    J Clin Oncol; 2009 Sep; 27(27):4619-29. PubMed ID: 19667279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
    Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE
    Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical management of adrenocortical carcinoma.
    Ranvier GG; Inabnet WB
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
    Fassnacht M; Allolio B
    Clin Endocrinol (Oxf); 2010 Nov; 73(5):561-5. PubMed ID: 20738315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update in adrenocortical carcinoma.
    Fassnacht M; Kroiss M; Allolio B
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives for mitotane treatment of adrenocortical carcinoma.
    Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary management of adrenocortical carcinoma.
    Zini L; Porpiglia F; Fassnacht M
    Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
    Tang Y; Liu Z; Zou Z; Liang J; Lu Y; Zhu Y
    Biomed Res Int; 2018; 2018():9362108. PubMed ID: 29967789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
    Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.
    Tőke J; Uhlyarik A; Lohinszky J; Stark J; Huszty G; Micsik T; Borka K; Reismann P; Horányi J; Igaz P; Tóth M
    Front Endocrinol (Lausanne); 2022; 13():952418. PubMed ID: 36246926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
    Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.